Drugs Trump Obesity Genetics

Reanalyses of tirzepatide trials and biobank data suggest GLP‑1 drugs work equally well for people with MC4R mutations or high BMI polygenic scores. In contrast, genetics does moderate success for lifestyle dieting and bariatric surgery. Pharmacology can thus level genetic disadvantages in obesity. — This reframes obesity policy and ethics by showing genetic risk can be pharmaceutically neutralized, shifting debates toward coverage, access, and responsibility in a post‑fatalism world.